FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1863145741> ?p ?o ?g. }

• W1863145741 endingPage "252" @default.
• W1863145741 startingPage "244" @default.
• W1863145741 abstract "Anaemia in low-risk myelodysplastic syndromes (MDS) is associated with reduced quality of life (QoL). Response to treatment with erythropoietin ± granulocyte colony-stimulating factor (G-CSF) is associated with improved QoL, but whether transfusion therapy with higher haemoglobin (Hb) target levels has similar effects is unknown. The objective for this prospective phase II Nordic multicentre trial was to assess QoL, response rate and physical function in elderly anaemic MDS patients treated to a target Hb level of >120 g/L.Thirty-six elderly patients with low- and intermediate-1 risk MDS received darbepoetin (DA) 300 μg/wk, with the addition of G-CSF if no response. If the Hb target was reached at 16 wk, treatment was maintained until week 26. Remaining patients were transfused to reach the target level for at least 8 wk. Twenty-seven patients completed the study. Response rate to DA ± G-CSF was 67% in evaluable patients and 56% according to intention to treat. Eighteen patients reached the target Hb level according to protocol. QoL scores for fatigue, dyspnoea, constipation, and physical, role and social functioning improved significantly during study, with similar results for transfused and untransfused patients. Maintaining Hb >120 g/L did not confer a higher transfusion rate, once the target was reached. In two of fourteen patients, magnetic resonance imaging T2* indicated cardiac iron overload, however, without association with ferritin levels.In elderly anaemic MDS patients, an increment in haemoglobin is associated with improved QoL, whether induced by growth factor treatment or transfusion therapy." @default.
• W1863145741 created "2016-06-24" @default.
• W1863145741 creator A5010254186 @default.
• W1863145741 creator A5010472135 @default.
• W1863145741 creator A5010539034 @default.
• W1863145741 creator A5012374853 @default.
• W1863145741 creator A5012869742 @default.
• W1863145741 creator A5023148872 @default.
• W1863145741 creator A5031248010 @default.
• W1863145741 creator A5040642952 @default.
• W1863145741 creator A5050171154 @default.
• W1863145741 creator A5051415122 @default.
• W1863145741 creator A5054512616 @default.
• W1863145741 creator A5066936951 @default.
• W1863145741 creator A5068471072 @default.
• W1863145741 creator A5076734151 @default.
• W1863145741 date "2011-07-26" @default.
• W1863145741 modified "2023-10-17" @default.
• W1863145741 title "Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions" @default.
• W1863145741 cites W1516581565 @default.
• W1863145741 cites W1541533982 @default.
• W1863145741 cites W1809229150 @default.
• W1863145741 cites W187238933 @default.
• W1863145741 cites W1931544110 @default.
• W1863145741 cites W1964336930 @default.
• W1863145741 cites W1970566157 @default.
• W1863145741 cites W1976180779 @default.
• W1863145741 cites W1979820704 @default.
• W1863145741 cites W1980671612 @default.
• W1863145741 cites W1985424121 @default.
• W1863145741 cites W1986544757 @default.
• W1863145741 cites W1996887331 @default.
• W1863145741 cites W2014207161 @default.
• W1863145741 cites W2014903824 @default.
• W1863145741 cites W2016870625 @default.
• W1863145741 cites W2022338634 @default.
• W1863145741 cites W2023968058 @default.
• W1863145741 cites W2027617536 @default.
• W1863145741 cites W2030094742 @default.
• W1863145741 cites W2050299158 @default.
• W1863145741 cites W2058820265 @default.
• W1863145741 cites W2060568260 @default.
• W1863145741 cites W2067804675 @default.
• W1863145741 cites W2070939442 @default.
• W1863145741 cites W2080361105 @default.
• W1863145741 cites W2093818690 @default.
• W1863145741 cites W2099727192 @default.
• W1863145741 cites W2157208233 @default.
• W1863145741 cites W2159156084 @default.
• W1863145741 cites W2165036959 @default.
• W1863145741 cites W2167571044 @default.
• W1863145741 cites W4245112841 @default.
• W1863145741 cites W4253916874 @default.
• W1863145741 doi "https://doi.org/10.1111/j.1600-0609.2011.01654.x" @default.
• W1863145741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21623919" @default.
• W1863145741 hasPublicationYear "2011" @default.
• W1863145741 type Work @default.
• W1863145741 sameAs 1863145741 @default.
• W1863145741 citedByCount "57" @default.
• W1863145741 countsByYear W18631457412012 @default.
• W1863145741 countsByYear W18631457412013 @default.
• W1863145741 countsByYear W18631457412014 @default.
• W1863145741 countsByYear W18631457412015 @default.
• W1863145741 countsByYear W18631457412016 @default.
• W1863145741 countsByYear W18631457412017 @default.
• W1863145741 countsByYear W18631457412018 @default.
• W1863145741 countsByYear W18631457412019 @default.
• W1863145741 countsByYear W18631457412020 @default.
• W1863145741 countsByYear W18631457412021 @default.
• W1863145741 countsByYear W18631457412022 @default.
• W1863145741 countsByYear W18631457412023 @default.
• W1863145741 crossrefType "journal-article" @default.
• W1863145741 hasAuthorship W1863145741A5010254186 @default.
• W1863145741 hasAuthorship W1863145741A5010472135 @default.
• W1863145741 hasAuthorship W1863145741A5010539034 @default.
• W1863145741 hasAuthorship W1863145741A5012374853 @default.
• W1863145741 hasAuthorship W1863145741A5012869742 @default.
• W1863145741 hasAuthorship W1863145741A5023148872 @default.
• W1863145741 hasAuthorship W1863145741A5031248010 @default.
• W1863145741 hasAuthorship W1863145741A5040642952 @default.
• W1863145741 hasAuthorship W1863145741A5050171154 @default.
• W1863145741 hasAuthorship W1863145741A5051415122 @default.
• W1863145741 hasAuthorship W1863145741A5054512616 @default.
• W1863145741 hasAuthorship W1863145741A5066936951 @default.
• W1863145741 hasAuthorship W1863145741A5068471072 @default.
• W1863145741 hasAuthorship W1863145741A5076734151 @default.
• W1863145741 hasConcept C126322002 @default.
• W1863145741 hasConcept C159110408 @default.
• W1863145741 hasConcept C2776694085 @default.
• W1863145741 hasConcept C2777767877 @default.
• W1863145741 hasConcept C2778248108 @default.
• W1863145741 hasConcept C2778319317 @default.
• W1863145741 hasConcept C2778534260 @default.
• W1863145741 hasConcept C2779171977 @default.
• W1863145741 hasConcept C2779951463 @default.
• W1863145741 hasConcept C2780007613 @default.
• W1863145741 hasConcept C2780817109 @default.
• W1863145741 hasConcept C2781404941 @default.

• next